CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 62 enrolled
Drug / intervention
Brentuximab Vedotin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03057795
NCT03057795Phase 2Active
CompareCT.gov

A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma

City of Hope Medical Center·interventional·Posted Feb 20, 2017·Updated May 1, 2026

In Brief

A Phase 2 clinical trial evaluating Brentuximab Vedotin, Laboratory Biomarker Analysis, and 1 other intervention for Classic Hodgkin Lymphoma and 2 related conditions. Active but no longer recruiting, targeting 62 participants across 6 sites.

Detailed Summary

This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and brentuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedFeb 20, 2017
Enrollment StartApr 3, 2017
Primary CompletionJan 30, 2021
Study CompletionFeb 25, 2027
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.4 years ago

Interventions

Brentuximab Vedotindrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Nivolumabbiological

Given IV